Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Inhibition of sphingosine kinase 2 downregulates the expression of c-Myc and Mcl-1 and induces apoptosis in multiple myeloma

Jagadish Kummetha Venkata, Ningfei An, Robert Stuart, Luciano J. Costa, Houjian Cai, Woodrow Coker, Jin H. Song, Kiwana Gibbs, Terri Matson, Elizabeth Garrett-Mayer, Zhuang Wan, Besim Ogretmen, Charles Smith, Yubin Kang

Blood (2014) 124 (12): 1915–1925.

https://doi.org/10.1182/blood-2014-03-559385

Published: 2014

Includes: Supplemental data

Journal Articles

A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells

Samantha Solito, Erika Falisi, Claudia Marcela Diaz-Montero, Andrea Doni, Laura Pinton, Antonio Rosato, Samuela Francescato, Giuseppe Basso, Paola Zanovello, Georgiana Onicescu, Elizabeth Garrett-Mayer, Alberto J. Montero, Vincenzo Bronte, Susanna Mandruzzato

Blood (2011) 118 (8): 2254–2265.

https://doi.org/10.1182/blood-2010-12-325753

Published: 2011

Journal Articles

Randomized Phase II Study of Two Schedules of Flavopiridol (Alvocidib, F) Given as Timed Sequential Therapy (TST) Wtih Ara-C and Mitoxantrone (FLAM) for Adults with Newly Diagnosed, Poor-Risk Acute Myelogenous Leukemia (AML)

Judith E. Karp, MD, John M. Pagel, MD, PhD, B. Douglas Smith, MD, Jacqueline M Greer, RN, D. Michelle Drye, RN, Kelly M. Smith, MD, Kathleen Dorcy, RN, John J Wright, MD, PhD, L. Austin Doyle, MD, PhD, Elizabeth Garrett-Mayer, PhD, Elihu H. Estey, MD

Blood (2010) 116 (21): 186.

https://doi.org/10.1182/blood.V116.21.186.186

Published: 2010

Journal Articles

Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide

Blood (2009) 113 (20): 4841–4852.

https://doi.org/10.1182/blood-2008-08-172726

Published: 2009

Includes: Supplemental data

Journal Articles

Myeloablative Allogeneic Bone Marrow Transplantation (AlloBMT) with T Cell Depletion (TCD) and Post-Transplant GM-CSF for Patients with High Risk MDS.

Erica Warlick, MD, Richard J. Jones, MD, Elizabeth Garrett-Mayer, PhD, Paul O’Donnell, MD, PhD, B. Douglas Smith, MD

Blood (2006) 108 (11): 5309.

https://doi.org/10.1182/blood.V108.11.5309.5309

Published: 2006

Journal Articles

A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia

Jeffrey E. Lancet, Ivana Gojo, Jason Gotlib, Eric J. Feldman, Jacqueline Greer, Jane L. Liesveld, Laura M. Bruzek, Lawrence Morris, Youn Park, Alex A. Adjei, Scott H. Kaufmann, Elizabeth Garrett-Mayer, Peter L. Greenberg, John J. Wright, Judith E. Karp

Blood (2006) 109 (4): 1387–1394.

https://doi.org/10.1182/blood-2006-04-014357

Published: 2006

Journal Articles

Outcomes of Autologous and Allogeneic BMT for Mantle Cell Lymphoma.

Yvette L. Kasamon, MD, Richard J. Jones, MD, Louis F. Diehl, MD, Hassan Nayer, MD, Michael J. Borowitz, MD, Elizabeth Garrett-Mayer, PhD, Richard F. Ambinder, MD, PhD, Ross A. Abrams, MD, Zhe Zhang, MS, Ian W. Flinn, MD, PhD

Blood (2004) 104 (11): 901.

https://doi.org/10.1182/blood.V104.11.901.901

Published: 2004

Journal Articles

A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations

Mark Levis, Kam-Fai Tse, B. Douglas Smith, Elizabeth Garrett, Donald Small

Blood (2001) 98 (3): 885–887.

https://doi.org/10.1182/blood.V98.3.885

Published: 2001

NARROW

Inhibition of sphingosine kinase 2 downregulates the expression of c-Myc and Mcl-1 and induces apoptosis in multiple myeloma

A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells

Randomized Phase II Study of Two Schedules of Flavopiridol (Alvocidib, F) Given as Timed Sequential Therapy (TST) Wtih Ara-C and Mitoxantrone (FLAM) for Adults with Newly Diagnosed, Poor-Risk Acute Myelogenous Leukemia (AML)

Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide

Myeloablative Allogeneic Bone Marrow Transplantation (AlloBMT) with T Cell Depletion (TCD) and Post-Transplant GM-CSF for Patients with High Risk MDS.

A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia

Outcomes of Autologous and Allogeneic BMT for Mantle Cell Lymphoma.

A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only